TY - JOUR
T1 - Current Strategy for Urban Measles Control
T2 - An Evaluation
AU - Nelson, Kenrad E.
AU - Kallick, Charles A.
AU - Resnick, Lewis
AU - Kallick, Sonia
AU - Gotoff, Samuel P.
AU - Levin, Stuart
PY - 1974/2/18
Y1 - 1974/2/18
N2 - Reported measles attack rates are substantially less since licensure of vaccine. Nevertheless, measles continues to be an important cause of morbidity among inner-city populations. In an urban epidemic that occurred after vaccine licensure, the deaths, encephalitis cases, and complication rates among hospitalized patients were similar to those in a prevaccine epidemic. In the earlier and later epidemics, respectively, 23.2% and 30.1% of hospitalized patients were less than 1 year old. In the later epidemic, attack rates were much greater in lower socioeconomic areas than in higher ones. Vaccine failure did not contribute greatly to the later epidemic. Childhood measles vaccination should be given high priority. As long as measles risk remains high, vaccination appears indicated for infants 6 to 9 months old from crowded, lower-income urban areas. These infants will need booster doses later to ensure immunity.
AB - Reported measles attack rates are substantially less since licensure of vaccine. Nevertheless, measles continues to be an important cause of morbidity among inner-city populations. In an urban epidemic that occurred after vaccine licensure, the deaths, encephalitis cases, and complication rates among hospitalized patients were similar to those in a prevaccine epidemic. In the earlier and later epidemics, respectively, 23.2% and 30.1% of hospitalized patients were less than 1 year old. In the later epidemic, attack rates were much greater in lower socioeconomic areas than in higher ones. Vaccine failure did not contribute greatly to the later epidemic. Childhood measles vaccination should be given high priority. As long as measles risk remains high, vaccination appears indicated for infants 6 to 9 months old from crowded, lower-income urban areas. These infants will need booster doses later to ensure immunity.
UR - http://www.scopus.com/inward/record.url?scp=0015944651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015944651&partnerID=8YFLogxK
U2 - 10.1001/jama.1974.03230200038006
DO - 10.1001/jama.1974.03230200038006
M3 - Article
C2 - 4405844
AN - SCOPUS:0015944651
SN - 0098-7484
VL - 227
SP - 780
EP - 783
JO - JAMA: The Journal of the American Medical Association
JF - JAMA: The Journal of the American Medical Association
IS - 7
ER -